Igm human elisa kit

The study was approved by the cantonal Ethics Committee of Zurich (KEK Nr. 2019-00150). All experiments were performed in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants and/or their legal guardians. Leftover maternal and cord blood samples were obtained from the University hospital Zurich, Switzerland. The study population comprised 30 full-term and 12 pre-term neonates. Out of these 42 samples, matched maternal blood was available for 26 full-term and 5 pre-term cord blood samples. Blood was centrifuged at 3,000 x g for 15 min at 4°C and sera were frozen at −20°C. IgG and IgM concentrations were determined by ELISA [IgG human ELISA Kit from Abnova (KA3817), IgM human ELISA Kit from Abnova (KA1855), Taipeh, China] according to the manufacturer's protocols. IgG transfer was calculated as proportion of the IgG concentration in cord blood to the IgG concentration in maternal blood ([IgG_cord/IgG_maternal]^*100), according to (44 (link)).

Blood serum samples from 40 IBD patients were provided by the Swiss IBD Cohort¹. The study of the serum samples was approved by the Cantonal Ethics Committee of Zurich (KEK-ZH Nr. 2007-1316). Venous blood samples (10 mL) from healthy volunteers (without a history of chronic gastrointestinal or autoimmune diseases) were collected into non-treated BD vacutainer blood collection tubes (BD Biosciences, Franklin Lakes, NJ, United States). Clotted blood was centrifuged at 3,000 × g for 15 min at 4°C and the supernatant serum was frozen at −20°C. For all serum samples, IgG and IgM concentrations were determined by ELISA Kits (IgG human ELISA Kit from Abnova, IgM human ELISA Kit from Abnova (Taipeh, China) according to the manufacturer’s protocol, using a serum dilution of 1:2.000.000 for IgG and 1:60.000 for IgM.